The latest news on Sysmex Inostics and OncoBEAM™
The collaboration will allow a comprehensive analysis of patient’s individual cancers including DNA sequencing, determination of protein expression and activity of therapy relevant cancer pathways. Indivumed staff will have access to tissue, blood and urine from consenting Geisinger patients who are already undergoing a surgical tumor resection. While Indivumed will concentrate on tissue testing to determine its molecular and biochemical profiles, Inostics will analyze plasma to determine therapy relevant cancer mutations and to monitor disease.
The overall goal is understanding the biological differences between tumors and how patients respond to treatments to support the implementation of personalized therapy.Back to news and press releases